Capital Ventures Llc Senour... Net Worth

The estimated Net Worth of Capital Ventures Llc Senour... is at least $363 mil dollars as of 11 May 2015. Capital Senour owns over 167,343 units of HTG Molecular Diagnostics Inc stock worth over $363,218 and over the last 10 years Capital sold HTGM stock worth over $0.

Capital Senour HTGM stock SEC Form 4 insiders trading

Capital has made over 1 trades of the HTG Molecular Diagnostics Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently Capital bought 167,343 units of HTGM stock worth $2,342,802 on 11 May 2015.

The largest trade Capital's ever made was buying 167,343 units of HTG Molecular Diagnostics Inc stock on 11 May 2015 worth over $2,342,802. On average, Capital trades about 167,343 units every 0 days since 2015. As of 11 May 2015 Capital still owns at least 756,704 units of HTG Molecular Diagnostics Inc stock.

You can see the complete history of Capital Senour stock trades at the bottom of the page.

Insiders trading at HTG Molecular Diagnostics Inc

Over the last 10 years, insiders at HTG Molecular Diagnostics Inc have traded over $5,630,772 worth of HTG Molecular Diagnostics Inc stock and bought 1,019,150 units worth $14,128,765 . The most active insiders traders include Plc Gsk, Holdings A/S Novo y Laurence W Lytton. On average, HTG Molecular Diagnostics Inc executives and independent directors trade stock every 64 days with the average trade being worth of $28,039. The most recent stock trade was executed by Stephen Barat on 8 June 2023, trading 888 units of HTGM stock currently worth $710.

What does HTG Molecular Diagnostics Inc do?

about htg molecular diagnostics: headquartered in tucson, arizona, htg's mission is to empower precision medicine at the local level. in 2013 the company commercialized its htg edge instrument platform and a portfolio of rna assays that leverage htg's proprietary nuclease protection chemistry. htg's product offerings have since expanded to include its htg edgeseq product line, which automates sample and targeted library preparation for next-generation sequencing. additional information is available at www.htgmolecular.com.

Complete history of Capital Senour stock trades at HTG Molecular Diagnostics Inc

HTG Molecular Diagnostics Inc executives and stock owners

HTG Molecular Diagnostics Inc executives and other stock owners filed with the SEC include:

• John Lubniewski,
  President, Chief Executive Officer, Director
• John L. Lubniewski,
  Pres, CEO & Director
• Shaun D. McMeans,
  Sr. VP, CFO, Sec. & Treasurer
• Shaun McMeans,
  Chief Financial Officer, Senior Vice President, Treasurer, Secretary
• Byron T. Lawson,
  Sr. VP & Chief Commercial Officer
• Timothy Johnson,
  Executive Chairman of the Board
• Byron Lawson,
  Senior Vice President and Chief Commercial Financial Officer
• Lee McCracken,
  Independent Director
• James LaFrance,
  Independent Director
• Donnie Hardison,
  Independent Director
• Michelle Griffin,
  Independent Director
• Harry George,
  Independent Director
• Ann Hanham,
  Lead Independent Director
• Laura Beggrow,
  Pres of Diagnostics
• Dr. Stephen A. Barat Ph.D.,
  Sr. VP of Therapeutics
• Dr. Marian Navratil Ph.D.,
  Sr. VP of R&D
• Dr. Patrick C. Roche,
  Sr. VP of R&D
• Dr. Debra A. Gordon,
  Sr. VP & Chief Legal Counsel
• Laura Lee Godlewski,
  Sr. VP of Fin. & Admin.
• Dr. Maureen T. Cronin Ph.D.,
  Sr. VP & Chief Scientific Officer
• Christopher P Kiritsy,
  Director
• Stephen Barat,
  Senior VP of Therapeutics
• Debra A Gordon,
  V.P. and Chief Legal Counsel
• Lewis Shuster,
  Director
• Plc Gsk,
  10% owner
• Don M Hardison,
  Director
• Holdings A/S Novo,
  10% owner
• Nv Qiagen,
  10% owner
• Patrick C. Roche,
  SVP Research & Development
• Spaght Ventures Ii Lpfsv Ii...,
  
• Donald W Grimm,
  Director
• Capital Ventures Llc Senour...,
  
• Tim B Johnson,
  Executive Chairman
• Laurence W Lytton,
  10% owner
• Thomas W. Dubensky,
  Director
• Laura Lee Godlewski,
  SVP Finance & Administration